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Abstract
Background: Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional receptor involved in receptor-
mediated endocytosis and cell signaling. The aim of this study was to elucidate the expression and mechanism of LRP1 in
hepatocellular carcinoma (HCC).
Methods: LRP1 expression in 4 HCC cell lines and 40 HCC samples was detected. After interruption of LRP1 expression in a
HCC cell line either with specific lentiviral-mediated shRNA LRP1 or in the presence of the LRP1-specific chaperone,
receptor-associated protein (RAP), the role of LRP1 in the migration and invasion of HCC cells was assessed in vivo and in
vitro, and the expression of matrix metalloproteinase (MMP) 9 in cells and the bioactivity of MMP9 in the supernatant were
assayed. The expression and prognostic value of LRP1 were investigated in 327 HCC specimens.
Results: Low LRP1 expression was associated with poor HCC prognosis, with low expression independently related to
shortened overall survival and increased tumor recurrence rate. Expression of LRP1 in non-recurrent HCC samples was
significantly higher than that in early recurrent samples. LRP1 expression in HCC cell lines was inversely correlated with their
metastatic potential. After inhibition of LRP1, low-metastatic SMCC-7721 cells showed enhanced migration and invasion and
increased expression and bioactivity of MMP9. Correlation analysis showed a negative correlation between LRP1 and MMP9
expression in HCC patients. The prognostic value of LRP1 expression was validated in the independent data set.
Conclusions: LRP1 modulated the level of MMP9 and low level of LRP1 expression was associated with aggressiveness and
invasiveness in HCCs. LRP1 offered a possible strategy for tumor molecular therapy.
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Introduction
Hepatocellular carcinoma (HCC) is one of most frequent
neoplasm worldwide [1], and has become a major cause of cancer-
related death globally, owing to its high potential of invasion and
metastasis. The molecular mechanism linked to invasion and
metastasis of HCC is not fully understood. Hence, investigation of
the underlying molecular mechanism may ultimately help in the
development of innovative therapeutic strategies against HCC.
The low-density lipoprotein receptor (LDLR)-related protein-1
(LRP1) is a member of LDLR family, which is ubiquitously
expressed in a variety of organs including adipose tissue, liver and
brain [2]. It consists of a 515 kDa heavy chain that contains four
clusters of ligand binding domains and a non-covalently associated
85 kDa light chain that contains a trans-membrane and
cytoplasmic domain [3]. The biological activity of LRP1 was
initially characterized as a clearance receptor for chylomicron
remnants and complexes of a2-macroglobulin with proteinases [4].
Subsequent work has revealed that this receptor recognizes several
classes of ligands, including serine proteinases, proteinase-inhibitor
complexes, and the matricellular proteins TSP1 and TSP2 [5,6,7].
Recent studies indicate that LRP1 can bind a large number of
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  (JF)cytoplasmic adaptor proteins via determinants located on its
cytoplasmic domain in a phosphorylation-specific manner, and
modulate the activity of other transmembrane receptors such as
integrins and receptor tyrosine kinases [8]. Since the expression
and activation of serine proteinases, urokinase plasminogen
activator (uPA), TSP-1, TSP-2 as well as the matrix metallopro-
teinases (MMPs) can regulate the tumor microenvironment, the
function of LRP1 as an endocytic receptor for diverse extracellular
mediators may represent one mechanism by which LRP1 may
regulate the tumor microenvironment and involve in tumor
progression and spreading.
Although a growing number of studies have demonstrated that
LRP1 is implicated in cancer progression, its precise role and
potential underlying mechanism in specific cancers remain conten-
tious [5]. Several studies have reported that low expression of LRP1
is closely related to aggressive tumor cells and advanced tumor
stages, such as human endometrial carcinoma [9], thyroid cancer
[10], Wilms tumors [11], lung cancer [12], breast and prostate
cancer [13]. While, other studies argued that high LRP1 expression
promotes breast cancer cell invasiveness, and LRP1 neutralization
could abrogate cell motility in both tumor and nontumor cells
despite the increased pericellular proteolytic activities of MMP2 and
uPA [14]. Therefore, the LRP1function intumor cellmigration and
invasion likely depends on the tumor cell type and the specific
extracellular proteins involved in these processes.
Recently, quantitative proteomics analysis of metastasis-related
proteins in HCC cells showed a decrease of LRP1 level in MHCC-
97H cell line with high metastasis potential, compared to low
metastatic cell line MHCC-97L [15]. We used a combination of
immunoprecipitation with mass spectrometry to develop an
extensive protein–protein ‘‘interactome’’ network centered on
tetraspanin CD151 in HCCLM3 cells, and identified LRP1 as an
important molecular partner for CD151 with regard to metastasis
of HCC [16,17,18], Therefore, LRP1 may play a specific role in
the migration and invasion of HCC cells, probably relying on the
specific molecular partner, which begs us for a closer look into the
role of LRP1 in HCC. The present study demonstrates that low
expression of LRP1 is a major contributor to the invasion-prone
phenotype of HCC, and inhibition of LRP1, coupled to the
increased expression and bioactivity of MMP9, enhances tumor
cell migration and invasion. Our results also show that low level of
LRP1 predicts an unfavorable prognosis of HCC after curative
resection in the 2 independent patient cohorts.
Materials and Methods
Cell Lines and Animals
HCC cell lines Hep3B (low-metastatic human HCC cell line,
American Type Culture Collection), SMMC-7721 (low-metastatic
human HCC cell line, Chinese Academy of Science Cell Bank
[19]), HCCLM3 and MHCC97L (human HCC cell lines with
stepwise metastatic potential [20] established at the Liver Cancer
Institute, Zhongshan Hospital, Fudan University) were used in this
study. Male, athymic BALB/c nude mice (8 weeks old; Shanghai
Institute of Material Medicine, Chinese Academy of Science,
Shanghai, China) were raised under specific pathogen-free
conditions. All animal work was performed in accordance with
protocols approved by the Shanghai Medical Experimental
Animal Care Commission. Ethical approval was obtained from
the Research Ethics Committee of Zhongshan Hospital.
Patients and Follow-up
Fresh HCC samples and their adjacent non-tumor samples were
obtained from 327 consecutive patients who underwent curative
HCC resection between 1997 and 2000 at the Liver Cancer
Institute of Fudan University [21]. HCC diagnosis was based on
World Health Organization criteria. Tumor differentiation was
defined according to the Edmondson grading system [22]. Liver
function was assessed using the Child–Pugh scoring system. Tumor
staging was determined according to the sixth edition of the tumor–
node–metastasis (TNM) classification of the International Union
Against Cancer. Ethical approval was obtained from the Research
Ethics Committee of Zhongshan Hospital, and written informed
consent was obtained from each patient. Follow-up was terminated
in March 2007. The median follow-up was 62 months (range, 4–
121 months). The follow-up procedures were described in detail in
ourearlierstudy[21].Treatmentmodalitiesafterrelapseweregiven
according to a uniform guideline as described [21].
RNA Extraction and Quantitative Real-time Polymerase
Chain Reaction (qRT-PCR)
Four HCC cell lines and 40 HCC samples selected blindly from
the above cohort, including 20 cases of HCC with early recurrence
(within 2 years after curative resection) and 20 cases of HCC
without early recurrence, were analyzed by qRT-PCR as described
previously [17], with slight modification. Primers of b-actin
as a control: sense: 59-AGCGAGCATCCCCCAAAGTT-39,
anti-sense: 59-GGGCACGAAGGCTCATCATT-39. Primers of
LRP1: 59-ACATATAGCCTCCATCCTAATC-39 and 59-TT-
CCAATCTCCACGTTCAT-39. Each sample was tested in
triplicate. The mean Ct value for the b-actin gene was subtracted
from the mean Ct value for LRP1 for each sample, using the
following formula: LRP1DCt=(mean LRP1Ct2mean b-actin Ct).
Thefold change(2
2LRP1DCt) oftheLRP1 expression levelrelative to
the b-actin expression level was calculated for each HCC sample.
Immunoblotting and Immunofluorescence Assay
Thirty micrograms of total cell extract protein was run on
sodium dodecyl sulfate-polyacrylamide gel electropheresis (SDS-
PAGE), transferred onto polyvinylidene difluoride membranes,
and incubated with the corresponding antibodies. The membranes
were developed with the enhanced chemiluminescence method
(Pierce, Rockford, IL, USA). Mouse anti-human LRP1 polyclonal
antibody (1:2000; Abnovus Biologicals UK) and rabbit anti-
human MMP9 polyclonal antibody (1:1000; Cell Signaling
Technology, Danvers, MA, USA) was used to detect the
expression of LRP1 and MMP9, respectively. GAPDH (1:5,000;
Chemicon, Temecula, CA, USA) was used as an internal control.
All experiments were performed in triplicate. HCCLM3 and
SMMC-7721 cells were used to detect the location of LRP1 by
immunofluorescence assay as described previously [23]. The slices
were assayed by fluorescence microscopy (Leica Microsystems
Imaging Solutions, Cambridge, UK).
Inhibition of LRP1: shRNA for LRP1 or receptor-associated
protein(RAP)
Lentiviral-mediated pGCSIL-GFP-shRNA-LRP1 was con-
structed (Shanghai Genechem, Shanghai, China). We constructed
4 shRNA-LRP1 vectors (pGCSIL-GFP-shRNA-LRP1) to silence
the expression of LRP1 in SMMC-7721 cells (SMMC-7721-
vshLRP1). The most effective shRNA targeting sequence for
LRP1 was as follows: 59- CGGAGTGGTATTCTGGTATAA-39.
Stable transfectant clones were identified by qRT-PCR and im-
munoblotting. LRP1-specific chaperone, recombinant RAP(1 mM,
novus Biologicals, USA) was preincubated with cells for 60 min-
utes at 37uC before the MMP9 expression and function analysis
was performed.
Role of LRP1 in HCC
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32775Cell Migration, Matrigel Invasion Assays and In Vivo
Metastasis Assays
Cell migration and Matrigel invasion assays were performed as
previously described [24]. A wound healing assay was used to
evaluate the ability of cell migration. Cells grew to 80%–90%
confluence in 24-well plates. A wound was made by dragging a
plastic pipette tip across the cell surface. The remaining cells were
washed three times to remove cell debris and incubated at 37uC
with serum-free medium. At the indicated times, migrating cells at
the wound front were photographed and compared. All
experiments were performed in triplicate. Cell invasion assays
were performed using 24-well transwells (8 mm pore size;
Minipore) precoated with Matrigel (Falcon354480; BD Bioscienc-
es). Cells on the lower surface of the membrane were fixed in 4%
paraformaldehyde and stained with Giemsa. Cells in 5 micro-
scopic fields (magnification, 6200) were counted and photo-
graphed. All experiments were performed in triplicates.
The in vivo metastasis assays were performed as the previously
described methods [16]. SMMC-7721-Mock and SMMC-7721-
vshLRP1 cells (8.0610
6) were injected intrahepatically by a 27-
gauge needle. Tumor volume was calculated using the following
formula: V=p/66length6width6height, and intrahepatic tumor
and lung metastases of SMMC-7721-Mock and SMCC-7721-
vshLRP1 were visualized with fluorescence stereomicroscopy
(Leica Microsystems Imaging Solutions).
Gelatin Zymography
The type IV collagenase activity of MMP9 in a conditioned
medium was determined by gelatin zymography. Culture medium
was prepared from either SMCC-7721, SMMC-7721-MOCK,
SMMC-7721-vshLRP1 or SMMC-7721 treated with RAP cells. A
total of 10
5 cells were cultured in 1 ml of serum-free DMEM for
48 h, then culture media was electrophoresed at 4uC in 10%
crosslinked SDS-PAGE, containing either 0.1% gelatin (Difco,
Detroit, MI, USA). Following electrophoresis, the gel was washed
with 2.5% Triton X-100 followed by incubation in Tris–HCl,
0.5 mM CaCl2, 10-6 M ZnCl2, pH 8.0, at 37uC for 16 h.
Coomassie brilliant blue staining was then carried out.
Construction of Tissue Microarrays and
Immunohistochemistry
Tissue microarrays were constructed as described in our earlier
study [21]. Immunohistochemical staining was performed as
described elsewhere [24]. The intensity of LRP1- and MMP9-
positive staining were measured mostly as described [21], based on
a computerized image system, including a Leica DFC420 charge-
coupled device camera and a Leica DM IRE2 microscope (Leica
Microsystems Imaging Solutions). Briefly, three representative
fields of each case were captured by the Leica QWin Plus v3
software under identical settings and magnification (6200). The
area of positive staining in a photograph was measured by Image-
Pro Plus v6.0software (Media Cybernetics, Inc.). The average
proportion (area of positive staining/total area) on each spot (three
images) was used to represent a particular sample. The expression
of LRP1 and MMP9 was classified into two subgroups based on
intensity, respectively (mean the average proportion as cutoff
value, LRP1
high, $45% of tumor section, and MMP9
high, $20%
of tumor section and LRP1
low, ,45%, and MMP9
low, ,20%).
Figure 1. Expression and location of LRP1 in HCC cell lines and HCC tissues. Relative LRP1 mRNA levels (A) and protein levels (B) in Hep3B,
SMMC-7721, HCCLM3 and MHCC-97L cells. (C) qRT-PCR showed LRP1 mRNA levels in HCC tissues with early recurrence were lower than that of HCC
tissues without recurrence. (D) Fluorescence staining analysis for LRP1 expression in HCCLM3 and S MMC7721 cells.
doi:10.1371/journal.pone.0032775.g001
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Statistical analysis was performed with SPSS 12.0 software
(SPSS, Chicago, IL, USA). Values are expressed as means 6
standard deviation. Student’s t test was used for comparison
between groups. Correlation analysis was performed between
LRP1 and MMP9. Overall survival (OS) and time to recurrence
were defined as described previously [25]. OS and the cumulative
recurrence rates were calculated by the Kaplan–Meier method
and the log rank test. Cox’s proportional hazards regression model
was used to analyze the independent prognostic factors. P,0.05
was considered statistically significant.
Independent validation
To further evaluate the prognostic performance of LRP1
expression, we validate in another independent cohort containing
an additional series of 161 patients who underwent curative HCC
resection in 2003 at the Liver Cancer Institute of Fudan
University. Clinicopathologic features of this cohort of patients
was described (Table S1). Immunohistochemistry, quantification
of LRP1 expression, and statistics were conducted using the same
methods.
Results
Low Expression of LRP1 was Correlated with High
Metastatic Potential in HCC
LRP1 expression was detected in 4 HCC cell lines with different
metastatic potential at the mRNA (Fig. 1A) and protein (Fig. 1B)
levels. qRT-PCR showed that LRP1 expression level in the highest
metastatic cell HCCLM3 was the lowest among 4 HCC cell lines
(Fig. 1A, P,0.05), in line with the results from immunoblotting
(Fig. 1B). We also examined the LRP1 mRNA expression in 40
cases of HCC. Strikingly, the LRP1 mRNA expression in non-
recurrent HCC tissues (without recurrence within 2 years after
curative resection) was 0.1260.0047, which was higher than that
in the early recurrence group (recurrence within 2 years after
Figure 2. LRP1 inhibition enhanced invasion of SMCC-7721 cells and increased MMP9 expression and bioactivity in vitro and in vivo.
(A) SMCC-7721 cells were successfully transfected with lentiviral-mediated pGCSIL-GFP-vshRNA-LRP1, and inhibition of LRP1 was validated by the
qRT-PCR and immunoblottting. (B) wound healing assay, magnification6100. (C) Transwell assay, magnification6200. (D) The expression of MMP9
in cells and the bioactivity of MMP9 in the supernatant were assayed by western blot and gelatin zymography (lower panel), respectively. (E) The
volume of SMMC-7721- vshLRP1-derived xenografts was larger than that of SMMC-7721-Mock-derived group. (F) Immunohistochemical staining for
xenografts showed that down-regulation of LRP1 enhanced the level of MMP9 expression in vivo. (G) In the SMCC-7721-Mock xenografts, intrahepatic
metastasis and lung metastasis were also markedly lower than those in the SMCC-7721-vshLRP1 groups.
doi:10.1371/journal.pone.0032775.g002
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cence assay demonstrated that LRP1 localized on the cytoplasm
membrane of HCCLM3 and SMMC-7721 cells (Fig. 1D).
Immunofluorescence intensity of LRP1 in SMMC-7721 cells
was stronger than that of HCCLM3 cells (Fig. 1D). The above
data demonstrated that low LRP1 expression was related to the
high metastatic potential in HCC.
LRP1 Inhibition Up-regulated MMP9 Expression and
Enhanced Mobility and Invasion of HCC Cells in vitro and
in vivo
We then determined the effect of LRP1 silencing on HCC cell
mobility and invasion. LRP1 knockdown in SMCC-7721 cells was
achieved by transfecting cells with pGCSIL-GFP-shRNA-LRP1
(Fig. 2A). Decreased expression of LRP1 in SMMC-7721 (.90%)
was validated by qRT-PCR and Immunoblotting (Fig. 2A).
Wound healing assay demonstrated accelerated wound closure
in SMMC-7721-vshLRP1 cells, compared with SMMC-7721-
Mock cells (Fig. 2B). Matrigel invasion assays showed markedly
increased numbers of invaded SMMC-7721 cells after down-
regulation of LRP1 expression using special shRNA (114.6618.6
vs. 277.7626.0, P=0.001) (Fig. 2C). Increased number of invaded
cells was also detected in SMMC-7721 cells blocked by LRP1-
specific chaperone RAP (114.6618.6 vs. 177.6622.5, P=0.019)
(Fig. 2C). But when recombinant tissue inhibitor of metallopro-
teinases-1(TIMP-1, abcam, 25 mmol/L)) was applied to block
MMP9 activity in SMMC-7721 cells treated with RAP, the
number of invasive cells was significantly higher in the SMMC-
7721 cells treated with RAP than the SMMC-7721 cells treated
with TIMP-1 and RAP, suggesting that TIMP-1 could reverse the
Figure 3. Expression of LRP1 and MMP9 in 327 cases of HCC. Hematoxylin & eosin staining of the tumor and corresponding peritumoral liver
tissues (A, B, C and D). The LRP1 staining was mostly detected in the cell membrane of tumor cells, stromal cells and peritumoral liver cells(E, F, G
and H). The expression of LRP1 protein had great variation in different tumor samples (F and H). the MMP9 protein was located in cytoplasm of
tumor cells, peritumoral liver cells, stromal fibroblasts and inflammatory cells (I, J, K and L). Representative cases were listed. Patient 1 had high LRP1
expression and low expression of MMP9 (F and J), and patient 2 showed low LRP1 expression and high MMP9 expression in tumor tissue (H and L).
The graph showed that the level of LRP1 protein expression was significantly down-regulated in tumors compared to that in the corresponding
peritumoral liver tissues (M). A scatter plot showed that LRP1 protein expression in 40 tumor tissues blindly chosen from 327 cases of HCC was
consistent with that of LRP1 mRNA (N). Scale bars: 100 mm.
doi:10.1371/journal.pone.0032775.g003
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gelatin zymography revealed that MMP9 expression and bioac-
tivity in SMMC-7721-vshLRP1 cells were enhanced when LRP1
in SMMC-7721 cells was down-regulated or blocked by RAP
(Fig. 2D).
We then performed the in vivo metastasis assay to determine the
metastasis potential of SMMC-7721 after LRP1 silencing. After
successful formation of liver orthotropic tumors, tumor size and
metastasis were assayed. The volume of SMMC-7721-Mock-
derived and SMMC-7721-vshLRP1-derived xenografts were
0.82760.440 and 1.75860.503 cm
3, respectively (P=0.007,
Fig. 2E). Immunohistochemical staining for xenografts showed
that down-regulation of LRP1 also enhanced the level of MMP9
expression in vivo (Fig. 2F). The pulmonary metastasis rate in the
SMMC-7721-vshLRP1 group was 83.3% (5/6), which was higher
than that in the SMMC-7721-MOCK xenografts (16.6%, 1/6). In
the SMCC-7721-Mock xenografts, intrahepatic metastasis were
also markedly lower than those in the SMCC-7721-vshLRP1
groups (16.6% vs. 83.3%) (Fig. 2G).
LRP1 Expression was a Beneficent Parameter for
Predicting Prognosis in HCC Patients
After identification of primary HCC and peritumoral tissues
using hematoxylin & eosin staining(Fig. 3A, B, C and D),
expression of LRP1 protein was investigated in tissue microarrays
consisting of 327 cases of HCC samples using immunohistochem-
istry (Fig. 3E, F, G and H). Immunoreactivity of LRP1 protein was
observed in in the cell membranes of tumor cells, stromal cells and
peritumoral liver cells (Fig. 3E, F, G and H). The expression of
LRP protein in HCC cells had great variation in different tumor
samples (Fig. 3. F and H). LRP1 protein expression in tumors was
significantly lower than that in the corresponding peritumoral liver
tissues in 327 cases of HCC (Fig. 3M; 44.8%618.5% vs.
53.3%627.1%, respectively, P,0.05, Fig. 3M). We have detected
the expression of LRP1 mRNA in the above 40 HCC samples,
and we compared the difference between LRP1 protein from
immunohistochemistical staining and LRP1 mRNA in the same
patients. A scatter plot revealed a significantly positive correlation
between LRP1 protein and mRNA in 40 cases of HCC tissues
(r=0.769, P,0.001, Fig. 3N).
Of the 327 tumors, 161 (49.2%) were ranked as low and 166
(50.8%) as high LRP1 expression. LRP1
low was significantly
correlated with vascular invasion (P=0.037), none encapsulation
(P=0.002), high TNM staging (P=0.043), and large tumor
(P,0.001). However, other clinical characteristics, including age,
sex, preoperative serum a-fetoprotein (AFP), liver cirrhosis, Child–
Pugh score, preoperative treatment, tumor number and differen-
tiation were not significantly related to the expression of LRP1
(Table 1).
The 3-, 5-, and 7-year OS rates in the whole cohort were
67.3%, 54.1% and 44.3% while cumulative recurrence were
36.7%, 45.6%, and 48.6%, respectively. Univariate analysis
revealed that tumor size, tumor number, microvascular invasion,
TNM staging and LRP1 expression were predictors for OS and
cumulative recurrence. Tumor differentiation, tumor encapsula-
tion and AFP were associated only with OS (Table 2). Individual
clinicopathological features that showed significance by univariate
analysis were adopted as covariates in a multivariate Cox
proportional hazards model. LRP1 was an independent prognostic
indicator for OS (P=0.010) and cumulative recurrence (P=0.031,
Table 2). The 3-, 5-, and 7-year OS in the LRP1
low group was
significantly lower than those in the LRP1
high group (52.4% vs.
83.8%, 40.9% vs. 67.5%, 35.3% vs. 52.2%, respectively, Fig. 4A).
The 3-, 5-, and 7-year cumulative recurrence rates in the LRP1
high
group were significantly lower than those in the LRP1
low group
(29.9% vs. 49.1%, 44.5% vs. 51.4%, 47.8% vs. 55.0%, respectively,
Fig. 4B).
Table 1. Correlation between LRP1 and clinicopathological
characteristics in 327 HCCs.
Variables LRP1 expression P value
% of Total area
Sex
Male 45.0614.6 0.489
Female 43.5614.2
Age, years
,52 44.3615.2 0.534
$52 45.3614.0
HBsAg
Positive 44.9614.3 0.776
Negative 44.3615.7
Liver cirrhosis
Yes 44.7614.5 0.839
No 45.2615.2
Preoperative treatment
Yes 45.1614.2 0.772
No 44.6614.9
Child–Pugh score
A4 4 . 8 614.5 0.824
B4 2 . 5 627.6
Serum AFP, ng/ml
#20 45.3614.7 0.533
.20 44.3614.5
Tumor number
Single 45.0614.1 0.472
Multiple 43.4616.9
Microvascular invasion
Yes 39.1616.0 0.037
None 45.3614.3
Tumor encapsulation
Complete 46.7614.1 0.002
None 41.6614.8
Tumor differentiation
I/II 45.8614.4 0.069
III/IV 42.6614.7
Tumor diameter(cm)
#54 7 . 4 614.1 ,0.001
.54 1 . 6 614.5
TNM stage
I/II 45.7613.8 0.043
III 41.7616.8
Note: Values are expressed as the mean 6 standard deviation.The student t test
was used for comparison between groups. Abbreviations: AFP, a-fetoprotein;
HBsAg, hepatitis B surface antigen. TNM, tumor-node-metastasis.
doi:10.1371/journal.pone.0032775.t001
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Patient Outcome
Previously, we identified that MMP9 expression was positively
correlated with poor prognosis of HCC patients in the same cohort
[21]. The MMP9 protein was observed incytoplasm of cells, stromal
fibroblasts and inflammatory cells (Fig. 3I, J, K and L). Spearman’s
correlation analysis showed a negative correlation between LRP1
and MMP9expression (r=20.291,P,0.001).Furthermore, we also
investigated the effect of combined LRP1 and MMP9 expression on
patient outcome. Patients were divided into four subgroups: (I)
LRP1
high/MMP9
high (n=56), (II) LRP1
low/MMP9
high (n=108),
(III) LRP1
high/MMP9
low (n=103), and (IV) LRP1
low/MMP9
low
(n=60). The HCCpatients with LRP1
low/MMP9
high had the worst
prognosis among the four subgroups (Fig. 4C and D).
Independent validation
Low level of LRP1 predicted an unfavorable prognosis in the
validation set containing 161 HCC patients (Fig. S1). The prognostic
value of LRP1expression was validated in independent data set using
Cox proportional hazards model analysis, and the results of which
demonstrated that LRP1was an independent prognostic indicator for
OS (P=0.001) and cumulative recurrence (P=0.010, Table S2).
Discussion
The present study described that LRP1 was lowly expressed in
HCC cell lines as well as in HCC specimens, consistent with the
expression oflow-densitylipoproteinreceptorpreviouslyreportedin
HCC cells [26]. Although we failed to construct a plasmid that
overexpressed LRP1, owing to its large molecular mass (,600 kDa)
[5], our results still provided powerful evidence to support that high
expression of LRP1 was associated with low metastatic ability of
HCC both in vivo and vitro. More importantly, we addressed low
level of LRP1 had unfavorably prognostic implication in the 2
independent cohorts of HCC patients.
Although several studies have implicated LRP1 in tumorigen-
esis, its precise role and potential underlying mechanisms remain
controversial. For example, several reports have shown that low
expression of LRP1 is closely related to the aggressive phenotype
of tumor cells derived from various tissues, such as human
prostate, thyroid, and breast cancer [9,27]. However, other studies
identified that inhibition of LRP1 expression and function
decreased cell migration and invasion [14,28,29]. Therefore, we
consider that the LRP1 function in tumor cell migration and
invasion may depend on the tumor cell type and the specific
extracellular proteins involved in these processes. In our institute,
quantitative proteomics analysis of metastasis-related proteins in
HCC has shown an enhanced expression of LRP1 in MHCC97L
cells (with low metastasis potential) compared with MHCC97H
cells (with high metastasis potential) [15]. Here, we further showed
that the low level of LRP1 in HCC cells associated with the
metastatic potential of HCC cells. First, we found that HCC cells
expressing low LRP1 were tend to have high metastatic potential.
Second, after down-regulation of LRP1 expression in low-
metastatic SMMC-7721 cells, the cells showed significantly
increased migration and invasion in vivo and in vitro. In
particular, clinical data demonstrated that malignant pathological
phenotypes were more frequent in patients with low LRP1
expression than those with high expression. Moreover, LRP1
expression was independent of other prognostic markers (large
tumor size, microvascular invasion, and multiple tumors) for both
OS and cumulative recurrence. So we draw the conclusion that
low expression of LRP1 does promote the metastasis and invasion
of HCC and may be a prognostic indicator for HCC.
LRP1 was first characterized as an endocytic receptor for
apolipoprotein-E-containing lipoprotein particles and for a2-
macroglobulin. Since then, .40 ligands have been identified,
including proteases, protease inhibitors, growth factors, extracel-
lular matrix proteins, and foreign toxins. By binding bifunctional
extracellular ligands and intracellular signaling-adaptor proteins,
Table 2. Univariate and multivariate analyses of factors associated with survival and recurrence in 327 HCCs.
Variables OS Cumulative recurrence
Univariate, P Multivariate Univariate, P Multivariate
HR 95%CI p value HR 95%CI p value
Sex (male vs. female) 0.767 NA 0.399 NA
Age, years (,52 vs. $52) 0.253 NA 0.691 NA
HBsAg (negative vs. positive) 0.535 NA 0.208 NA
Liver cirrhosis (yes vs. no) 0.615 NA 0.387 NA
Preoperative treatment (yes vs. no) 0.140 NA 0.203 NA
Child–Pugh score (A vs. B) 0.169 NA 0.152 NA
Serum AFP (#20 vs. .20 ng/mL) 0.028 NS 0.323 NA
Tumor diameter (.5 vs. #5c m ) ,0.001 1.377 1.021–1.856 0.036 0.015 1.414 1.038–1.926 0.028
Tumor number (multiple vs. single) 0.001 1.782 1.244–2.552 0.002 0.009 1.707 1.146–2.541 0.008
Microvascular invasion (yes vs. none) ,0.001 1.878 1.162–3.035 0.010 0.002 2.196 1.322–3.650 0.002
Tumor encapsulation (none vs.
complete)
,0.001 NS 0.083 NA
Tumor differentiation (I/II vs. III/IV)) 0.018 NS 0.070 NA
TNM stage (I/II vs. III) ,0.001 NA ,0.001 NA
LRP1 expression (low vs. high) ,0.001 1.484 1.100–2.003 0.010 0.015 1.406 1.032–1.916 0.031
Abbreviations and Note: OS, overall survival; NA, not adopted; NS, not significant; AFP, a-fetoprotein; HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis;
95%CI, 95% confidence interval; HR, Hazard ratio; Cox proportional hazards regression model.
doi:10.1371/journal.pone.0032775.t002
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receptors with cell signaling activity [30]. By binding adaptor
proteins, LRP1 also directly regulates the activity of various cell
signaling enzymes, including ERK/MAP kinase, PI3K, and c-Jun
NH2-terminal protein kinase [5]. The diverse activities of LRP1
suggest a model in which this receptor functions as a ‘‘sensor’’ of
the cellular microenvironment. Such activity should be highly
relevant to cancer because it is now widely accepted that a tumor
and its microenvironment actively and reciprocally interact at all
stages of cancer progression. To determine how LRP1 promotes
HCC cell migration and invasion, we focused on elucidating the
relationship between LRP1 and MMPs which has been reported
to participate closely in tumor progression in HCC [31]. Here, we
found that LRP1 silencing significantly increased the expression
and bioactivities of MMP9 in SMMC-7721 cells. Our results also
showed a negative correlation between LRP1 and MMP9 protein
expression by correlation analysis in HCC tissues, though we did
not detect MMP9 activity owing to the lack of effective measures.
The extracellular subunit (a-chain) of LRP1 harbors four ligand-
binding clusters that are involved in the specific recognition of
extracellular ligands [32]. Recently, multiple lines of evidence have
shown a tight link between LRP1 and MMPs [33]. Furthermore,
recent study reported MMPs may be modulated by their cellular
receptors that mediate their rapid internalization and degradation
[5]. Direct evidence provided by Hahn–Dantona et al. has
revealed that cell lines genetically deficient in LRP1 have
diminished capacity to mediate catabolism of MMP9, and the
assays in vitro have demonstrated the direct high-affinity
interaction between MMP9 and LRP1 [34]. Our previous study
showed the importance of MMP9 regulation in HCC, moreover, it
involved a variety of processes associated with progression and
metastasis of HCC [21]. Thus, we propose that LRP1 might
regulate tumor migration and invasion by altering the level of
MMP9.
In general, LRP1 modulates MMP9 expression and low level of
LRP1 in HCC cells is associated with tumor aggressiveness in
HCC. Low level of LRP1 predicts an unfavorable prognosis of
HCC after curative resection. LRP1 may offer a possible strategy
for tumor molecular therapy.
Supporting Information
Figure S1 Prognostic implication was assessed by
Kaplan–Meier analysis and log-rank tests in validation
set consisting of 161 HCC patients. HCC patients with high
LRP1 expression had better prognosis in terms of overall survival
(A) and cumulative recurrence (B).
(TIF)
Figure 4. Prognostic significance was assessed by Kaplan–Meier analysis and log-rank tests. HCC patients with low LRP1 expression had
poorer prognosis in terms of overall survival (A) and cumulative recurrence (B). HCC patients with LRP1
low/MMP9
high showed the worst prognosis
among the four subgroups (C and D, group I LRP1
high/MMP9
high (n=56), group II LRP1
low/MMP9
high (n=108), group III LRP1
high/MMP9
low (n=103),
group IV LRP1
low/MMP9
low (n=60)).
doi:10.1371/journal.pone.0032775.g004
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